HomeCompareDNB vs PFE

DNB vs PFE: Dividend Comparison 2026

DNB yields 1.64% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $28.5K in total portfolio value· pulled ahead in Year 9
10 years
DNB
DNB
● Live price
1.64%
Share price
$9.15
Annual div
$0.15
5Y div CAGR
-10.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$55.20
Full DNB calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DNB vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNB
Annual income on $10K today (after 15% tax)
$139.34/yr
After 10yr DRIP, annual income (after tax)
$46.92/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,272.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNB + PFE for your $10,000?

DNB: 50%PFE: 50%
100% PFE50/50100% DNB
Portfolio after 10yr
$35.3K
Annual income
$13,156.96/yr
Blended yield
37.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DNB
Analyst Ratings
8
Buy
7
Hold
Consensus: Buy
Price Target
$19.17
+109.5% upside vs current
Range: $12.00 — $24.00
Altman Z
0.6
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNB buys
0
PFE buys
0
No recent congressional trades found for DNB or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNBPFE
Forward yield1.64%6.13%
Annual dividend / share$0.15$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-10.9%13.2%
Portfolio after 10y$21.1K$49.6K
Annual income after 10y$55.20$26,258.71
Total dividends collected$949.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$19.17$27.50

Year-by-year: DNB vs PFE ($10,000, DRIP)

YearDNB PortfolioDNB Income/yrPFE PortfolioPFE Income/yrGap
1$10,846$146.07$9,153$693.39+$1.7KDNB
2$11,737$131.92$8,593$849.25+$3.1KDNB
3$12,678$118.88$8,336$1,066.78+$4.3KDNB
4$13,672$106.92$8,437$1,384.80+$5.2KDNB
5$14,725$96.02$9,013$1,875.40+$5.7KDNB
6$15,842$86.11$10,306$2,680.72+$5.5KDNB
7$17,028$77.15$12,820$4,101.38+$4.2KDNB
8$18,289$69.05$17,673$6,826.70+$616.00DNB
9← crossover$19,631$61.76$27,543$12,591.86$7.9KPFE
10$21,060$55.20$49,560$26,258.71$28.5KPFE

DNB vs PFE: Complete Analysis 2026

DNBStock

Dun & Bradstreet Holdings, Inc. provides business decisioning data and analytics in North America and internationally. It offers finance and risk solutions, including D&B Finance Analytics, an online application that offers clients real time access to its information, comprehensive monitoring, and portfolio analysis; D&B Direct, an application programming interface (API) that delivers risk and financial data directly into enterprise applications for real-time credit decision making; D&B Small Business, a suite of powerful tools that allows SMBs to monitor and build their business credit file; D&B Enterprise Risk Assessment Manager, a solution for managing and automating credit decisioning and reporting; and InfoTorg, an online SaaS application. The company also provides risk and compliance solutions, such as D&B Supplier Risk Manager that provides insights to help certify, monitor, analyze, and mitigate risk across the supply chain; D&B Onboard to provide comprehensive insights into businesses to facilitate KYC/AML compliance, as well as to minimize financial, legal, and reputational risk exposure; and D&B Beneficial Ownership that offers risk intelligence on ultimate beneficial ownership. It offers sales and marketing solutions, including D&B Connect, a self-service data management platform; D&B Optimizer, an integrated data management solution; D&B Rev.Up ABX, an open and agnostic platform that aligns marketing and sales teams to deliver an optimal and coordinated buying; D&B Hoovers, a sales intelligence solution; D&B Audience Targeting, which helps clients to reach the right audiences with the right messages; D&B Visitor Intelligence that turns web visitors into leads; and D&B Direct, an API-enabled data management solution that delivers valuable customer insights into CRMs, marketing automation, and other marketing applications for on-demand business intelligence. The company was founded in 1841 and is headquartered in Jacksonville, Florida.

Full DNB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DNB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNB vs SCHDDNB vs JEPIDNB vs ODNB vs KODNB vs MAINDNB vs JNJDNB vs MRKDNB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.